Internal Medicine

A new cohort analysis suggest one-year intravitreal treatment burden can be significantly reduced when patients are only administered brolucizumab.

A new contribution of data evidences the "controversial" use of concomitant steroids in patients who do not benefit from monotherapy anti-VEGF.

New data suggests the number of prescriptions for SGLT2 inhibitors in the US has doubled since 2015 with prescriptions for GLP-1 receptor agonists tripling during the same time period.

A new study shows BCVA scores and blood levels of AA/EPA significantly improved in treated patients with dry AMD or Stargardt disease at 24 weeks.

An investigation into the diffusion, capacity and drug concentrations showed predictable flexibility with the novel ophthalmic implant device.

Matthew Cunningham, MD, explains the need for greater inclusion of impacted races and ethnicities in ophthalmic clinical trials.

The approval expands the indication for Qelbree to all patients with ADHD aged 6 years and older, and provides adult patients their first novel non-stimulant option in 20 years.

A study shows the Visceral Sensitivity Index could help identify anxiety and health-related quality of life burden in patients with IBS or IBD.

Nancy Holekamp, MD discusses the substantial emotional burden and impact on independence of GA reported in the Geographic Atrophy Insights Survey.

Data from a randomized clinical trial in 139 patients followed for 12 months suggests time-restricted eating was associated with a non-significant 1.9 kg difference in weight loss compared to calorie restriction.

Stephanie Lovinsky-Desir, MD, MS, discusses key findings from the 2022 ALA State of the Air Report.

Mehdi Mirsaeidi, MD, MPH, Director of the ILD and Sarcoidosis Program at the Jacksonville College of Medicine, joins Lungcast to review the rare disease for Sarcoid Awareness Month.

Erica Marsh, MD, MSCI, discusses the role of new drug classes like GnRH antagonists, as well as the adoption of remote screening options following COVID-19 response.

Erica Marsh, MD, MSCI, discusses the need for improved patient involvement and open discussion in the highly prevalent, potentially psychologically impactful condition.

The 2022 State of the Air report from the American Lung Association highlights growing disparities in coastal-based ozone and particle pollution, amid wildfires and shifts in regulatory policies.

The company reported interim results at a meeting this week showing multiple formulations were tolerable and safe. Next comes a phase 2 trial.

About 1 in 5 recent novel drug approvals were based on data extrapolated to a broader patient population or in regard to a concomitant drug use, including the controversial aducanumab indication from 2021.

Bianca K. Frogner, PhD, discusses the prevalence of burnout and job dissatisfaction observed across various health care worker roles and settings.

The investigative gene therapy achieved significant phase 3 endpoints, after receiving feedback from the FDA on its efficacy outcomes in 2020.

The most common comorbidities for adults were hypertension, hyperlipidemia, and diabetes.

Data show the life expectancy of Hispanic and non-Hispanic Black Americans decreased by more than 3 years during the pandemic.

Using a trio of diet indices, investigators provide insight into the relationship between adherence to plant-based diets and metabolites linked to decreased risk of type 2 diabetes.

A study highlights methods to define hydroxyurea exposure as means of understanding hematologic benefit derived from the first-line drug for children.

A survey analysis suggests the worst of turnover in the workforce occurred in 2020, but focus is needed to recover health care workers from specific fields.

An ophthalmologist provides insight into the harms of excessive blue light, and simple consumer resolutions.

Dr. Gregory Weiss discusses prediabetes screening in the US as a method help quell the growing diabetes epidemic in younger populations.

Steve Nissen, MD, reviews the promising phase 1 APOLLO findings, and details what needs to be investigated next for the siRNA.

Dr. Rafael Pérez-Figueroa talks about how the pandemic has exacerbated racial inequities on multiple levels saying that people of color have been overrepresented in jobs with high exposure to COVID-19, leading to disproportionate infections and death.

New phase 1 APOLLO data show the investigative single-dose siRNA infusion may address an inherent risk factor for severe cardiovascular events.